Background: Much attention has been recently focused on the role of fertility-sparing surgery in patients with ovarian cancer. However, few data are currently available on the feasibility of conservative approaches in women with disease extending beyond the ovaries. Aim: This review article aims at summarizing the oncologic and obstetric outcome of patients with stage II-III ovarian cancer treated with fertility-sparing surgery. We also describe a successful conservative management of a stage IIC endometrioid ovarian carcinoma. Methods: A literature search through Medline was carried out to locate published articles using the following keywords for selection: ‘Fertility-sparing surgery and ovarian cancer'. From every single case series, we retrieved data on patients with stage II-III disease submitted to conservative surgery. Results: We identified 21 patients with stage II-III disease receiving fertility-sparing surgery. Recurrent disease was observed in 9 women (42.8%), and 5 (23.8%) of them died of disease. In contrast, a successful obstetric outcome has been reported in 3 cases (14.2%). Conclusions: Radical surgical staging remains the standard of care for all women with stage II-III disease. A fertility-sparing approach may be considered only in the presence of a favorable histology and a very strong fertility desire.

1.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2.
Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al: Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(suppl 1):S161-S192.
3.
Colombo N, Parma G, Lapresa MT, Maggi F, Piantanida P, Maggioni A: Role of conservative surgery in ovarian cancer: the European experience. Int J Gynecol Cancer 2005;15(suppl 3):206-211.
4.
Eskander RN, Randall LM, Berman ML, Tewari KS, Disaia PJ, Bristow RE: Fertility-preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol 2011;205:103-110.
5.
Morice P, Wicart-Poque F, Rey A, El-Hassan J, Pautier P, Lhommé C, de Crevosier R, et al: Results of conservative treatment in epithelial ovarian carcinoma. Cancer 2001;92:2412-2418.
6.
Morice P, Leblanc E, Rey A, Baron M, Querleu D, Blanchot J, et al: Conservative treatment in epithelial ovarian cancer: results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Française d'Oncologie Gynécologique). Hum Reprod 2005;20:1379-1385.
7.
Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, et al: Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol 2008;110:345-353.
8.
Fruscio R, Corso S, Ceppi L, Garavaglia D, Garbi A, Floriani I, et al: Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. Ann Oncol 2013;24:138-144.
9.
Duska LR, Chang YC, Flynn CE, Chen AH, Goodman A, Fuller AF, et al: Epithelial ovarian carcinoma in the reproductive age group. Cancer 1999;85:2623-2629.
10.
Raspagliesi F, Fontanelli R, Paladini D, di Re EM: Conservative surgery in high-risk epithelial ovarian carcinoma. J Am Coll Surg 1997;185:457-460.
11.
Kajiyama H, Shibata K, Mizuno M, Umezu T, Suzuki S, Nawa A, et al: Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery. Br J Cancer 2011;105:1288-1294.
12.
Benjamin I, Morgan MA, Rubin SC: Occult bilateral involvement in stage I epithelial ovarian cancer. Gynecol Oncol 1999;72:288-291.
13.
Munnell EW: Is conservative therapy ever justified in stage I (IA) cancer of the ovary? Am J Obstet Gynecol 1969;103:641-653.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.